1. Background {#sec1}
=============

Anemia is a condition that develops when there is no sufficient healthy red blood cell, which is characterized either by a reduction in HGB, RBC or HCT count below normal levels \[[@B1]--[@B4]\]. As per the National Comprehensive Cancer Network (NCCN) guideline, anemia is defined as HGB ≤ 11 g/dl or ≥ 2 g/dl below the baseline. Cancer is one of the most frequent conditions associated with anemia of chronic disease; meantime, anemia is a common complication of cancer \[[@B5]\]. The estimated prevalence of anemia varies ranging from 30% to 90% of cancer patients during the course of their diseases \[[@B2], [@B5], [@B6]\].

Cancer-related anemia may occur as a direct effect of neoplasm, by the sensitization of the immune system, or as a result of the cancer treatment whether surgery, radiotherapy or chemotherapy \[[@B7], [@B8]\]. Cancer itself can directly cause or exacerbate anemia either by suppressing hematopoiesis through bone marrow infiltration or production of cytokines that lead to iron sequestration, inhibit release and synthesis of endogenous erythropoietin, reduce the response of erythroid progenitor cells to erythropoietin, which ultimately impair erythropoiesis \[[@B9]--[@B11]\].

Tumor cells are known to produce cytokines such as IL-1, interferon-*γ*, Il-6 and TNF-*α* that may be able to decrease HGB levels by hemolysis, suppression of erythropoiesis, and impairment of erythropoietin response of erythroid medullary precursors \[[@B8], [@B12], [@B13]\].

Blood loss can result from hemorrhage of the tumor itself (e.g., hepatoma, gastrointestinal, bladder, gynecologic) \[[@B10], [@B14]\] and organ damage can further exacerbate anemia from cancer.

Anemia is a major contributing factor to tumor hypoxia, which worsens the results of radiotherapy and chemotherapy, contributes to the progression of cancer and prolongs the duration of the treatment time and lessens the survival rate \[[@B12], [@B15], [@B16], [@B18]\]. Furthermore, anemia causes energy imbalance and emotional distress (fatigue) \[[@B21]\].

2. Methods {#sec2}
==========

2.1. Study Setting and Study Population {#sec2.1}
---------------------------------------

The study was undertaken at Tikur Anbessa Specialized Hospital from April to May 2014, Addis Ababa, Ethiopia. Among the treatment-naïve newly diagnosed confirmed solid cancer patients visited the radiotherapy center during the study period, 422 study participants were determined with the help of a single population proportion. Patients on follow up for chemotherapy or radiotherapy or surgery, with confirmed hematologic malignancy, who took anemia correction treatment, were excluded from the study.

2.2. Data Collection {#sec2.2}
--------------------

Data on the socio-demographic and clinical characteristics of the study participants were collected using a pretested structured questionnaire by interview and review of medical records. About 4 ml of venous blood was collected by an experienced laboratory technologist from each study participant for HGB, MCV, MCH, and MCHC analyses. These parameters were determined using the hematology analyzer Cell-Dyn 1800 (Abbott Laboratories Diagnostics Division, USA). To ensure the quality of data, pre-testing was done on patients being managed at the radiotherapy center before the study. The performance of the hematology analyzer was controlled by running quality control material alongside the study participant\'s sample. In addition, all flagged specimen was subjected to the manual differential to confirm the results.

2.3. Statistical Analysis {#sec2.3}
-------------------------

The data were cleaned, edited, checked for completeness, processed, and then entered into Epi Info version 3.5.3 and transported to SPSS version 16 statistical software. Chi-square and Odd\'s ratio were computed to see association and relationships between prevalence and severity of anemia with risk factors. *p*-value \< 0.05 was considered as statistically significant.

2.4. Ethical Consideration {#sec2.4}
--------------------------

Ethical clearance and approval were obtained from Departmental Research and Ethical Review Committee of Addis Ababa University, Department of Medical Laboratory Science. Permission for the conduct of the study was also obtained from the University Hospital. After study participants were informed about the objectives of the study and assuring confidentiality of their data, written informed consent was taken from all the participants.

3. Results {#sec3}
==========

3.1. Distribution of Socio-Demographic Factors {#sec3.1}
----------------------------------------------

Out of 422 respondents, 278 (66%) were females and the rest 144 (34%) were males. From the age category, the majority of respondents, 153 (36%) fell into 35--49 age group with age range between 18--80 years and a median age of 45. Two hundred twenty-seven (53.8%) and three hundred twenty-one (76.1%) respondents were urban dwellers and married, respectively. More than half of the respondents were illiterate and 156 (37.0%) patients were housewife ([Table 1](#tab1){ref-type="table"}).

3.2. Prevalence of Anemia {#sec3.2}
-------------------------

A total number of 422 cancer patients, who were first diagnosed at TASH, Radiotherapy center of Addis Ababa University during April--May 2014 were searched and enrolled for analysis. The types of cancer included were gynecologic (122 cases), Breast (96 cases), Nasopharyngeal (32 cases), colorectal (30 cases), Soft tissue sarcoma (29 cases), head and neck cancers (19 cases), thyroid (14 cases), hepatoma (8 cases), and other cancers (72 cases) ([Table 2](#tab2){ref-type="table"}).

The hemoglobin level for the whole patients ranged from 4.6 g/dl to 18.9 g/dl with a mean of 12.6 ± 2.3 (mean ± SD). The mean hemoglobin for male patients was 13.3 ± 2.5 and for female patients, 12.2 ± 2.1 g/dl. More than 1/3 of the anemic patients (68%) remained untreated for anemia. Only 25.8% and 6.2 % of anemic patients were treated with transfusion and iron respectively. The mean trigger hemoglobin for transfusion was 7.7 ± 1.7 (mean, SD) g/dl.

Anemia was diagnosed in 97 of the 422 patients (23%) and mean concentration (± SD) of HGB was 13.5 ± 1.5 g/dl in 325 non anemic patients while that was 9.4 g/L ± 1.6 g/dl in 97 anemic patients. Overall, the prevalence of anemia at diagnosis of cancers was 23.0% in unclassified cancers, and higher anemia prevalence was noted in gynecologic (37.7%) and colorectal cancers (26.7%) ([Table 2](#tab2){ref-type="table"}) Majority of the anemia (83.5%) was mild-moderate type whereas 11.3% and 5.2% were severe and life-threatening type ([Figure 1](#fig1){ref-type="fig"}).

Among the anemic solid cancer patients, anemia was morphologically categorized based on MCV and MCHC values using the cut off values in [Table 3](#tab3){ref-type="table"}.

Accordingly, from the total anemic patients, half of anemia (50.5%) was normocytic anemia, in which normocytic normochromic is 22.7% and normocytic hypochromic is 26.8%, and others were (47.4%) microcytic anemia, in which microcytic hypochromic is 30.9% and microcytic normochromic is 16.5%), and macrocytic anemia (2.1%) ([Figure 2](#fig2){ref-type="fig"}).

3.3. Risk Factors Associated with the Severity of Anemia {#sec3.3}
--------------------------------------------------------

Patients with bleeding history suffered more severe anemia as compared to a patient without bleeding history with *p*-value \< 0.05. Nevertheless, there was no statistically significant difference found in gender and age group among the severity of anemia ([Table 4](#tab4){ref-type="table"}).

3.4. Risk Factors for the Occurrence of Anemia {#sec3.4}
----------------------------------------------

In Bivariate analysis, the occurrence of anemia showed statistically significant association with gender, age group, bleeding history, tumor type, tumor stage and ECOG performance status with *p*-value \< 0.05.

When multivariate analysis was computed for these variables, a statistically significant association was noted only between the occurrence of anemia with bleeding history and ECOG performance status while considering other variables as confounders.

Patients complained of bleeding history were 4 times more likely to develop anemia than those lacking bleeding history (AOR = 3.628; 95% CI 1.800--7.314).

Patients with ECOG performance status of 3 were 3 times more prone to develop anemia than patients of 0 ECOG performance score (AOR = 3.344; 95% CI 1.410--7.927) ([Table 5](#tab5){ref-type="table"}).

4. Discussion {#sec4}
=============

Anemia in cancer patients observed as a result of the malignancy itself, anti-cancer treatment, blood losses, nutritional deficiencies, hemolysis, endocrine disorders, or inflammatory cytokines associated with chronic diseases. In our data, 422 treatment-naïve, newly diagnosed solid cancer patients in TASH, Radiotherapy center were included for this analysis. According to this study, the overall prevalence of anemia across different tumor was 23%, which is higher than the study conducted in China, 18.98% \[[@B19]\]. However, our finding is lower than the reports made by other researchers that showed 39.3%, 35%, 41%, 54.4%, 54.7%, and 55.7% in Europe, Australia, USA, Thailand, India, and Belgium, respectively \[[@B11], [@B17], [@B22], [@B24]--[@B26]\]. The low prevalence in our study is because of the difference in definition of anemia, study population and survey period.

As our report revealed, the most common cases noted were gynecologic issues (28.9%) followed by breast carcinoma (22.7%), our results are similar to those of a study conducted in Thailand, where gynecologic (30.6%) and breast cancers (26.2%) scored the first two ranks among the observed tumor types \[[@B25]\].

The prevalence of anemia was varied by tumor type. Our study demonstrated that 37.7% and 26.7% of gynecologic and colorectal cancer patients were anemic, respectively. This finding is lower with the report in Europe and Australia, which revealed 49.1% and 65% of gynecologic cancer patients were anemic at enrollment, respectively \[[@B20], [@B23]\]. This may be attributed to the difference in the definition of anemia and study design used.

Females and elderly patients with ≥ 65 years ranked higher anemia prevalence rates. We found a similar result in China, Sudan, Belgium \[[@B19], [@B21], [@B26]\]. In our survey, females are more anemic than males because of the fact that the majority of the cancer cases noted are gynecologic and the majority of gynecologic patients (53.7%) complained of bleeding history. The primary possible reason for the higher anemia proportion in elder than younger patients is due to the fact that as one gets older, there is a physiological change. As a result of this, for example, there is a decline in hematopoietic stem cell reserves and proliferation capacity, which leads to suppression of erythropoiesis.

Our study showed two factors were significantly associated with the occurrence of anemia, namely ECOG Performance score and bleeding history. Patients with ECOG Performance status 3 were 3.344 times at a higher risk of developing anemia than patients of 0 ECOG performance score, which is in agreement with the study done in the USA \[[@B6]\].

Our study also indicated that patients with bleeding history were 4 times at a higher risk of developing anemia than those patients lacking bleeding history. This finding is similar to reports made in India and China \[[@B17], [@B19]\] which revealed that bleeding from the tumor were major contributing factors for the occurrence of anemia in patients with solid malignancies. In our study, a majority of the anemic gynecologic patients were complaining of bleeding history 34/97 (35%), which is a contributing factor for the higher (37.7%) anemia prevalence in gynecology among observed tumor types.

In our data, the majority of the anemia (83.5%) was mild to moderate type. The mean trigger hemoglobin level for initiating transfusion in our data was 7.7 g/dl, which is lower as compared to reports made in ACAS (9.5 g/dl), Thailand (8.6 g/dl), Thailand (9.3 g/dl) and ECAS (9.7 g/dl) \[[@B12], [@B22], [@B23], [@B25]\]. The possible justifications for the low mean trigger hemoglobin level in our study are due to variation among Doctors\` decision in initiating anemia supportive treatment and also as a result of the high frequency of Grade 3 anemia when compared to other findings.

Regarding the anemia treatment patterns, our data showed that anemia was treated in 32% of patients with anemia. Our result was similar to the reports made in ECAS \[[@B22]\] and ACAS \[[@B23]\] in which 38.9% and 41% of patients with anemia were treated for their anemia before commencing anti-tumor agents, respectively, whereas it was higher compared to that of Thailand \[[@B25]\], in which 22.3% of patients with anemia got anemia correction treatment prior to commencing anti-cancer treatment. The most commonly used supportive treatment for anemia correction was blood transfusion (25.8%), which is in agreement with that of Thailand and ACAS (36%) \[[@B22], [@B23]\].

Anemia prevalence was also varied by tumor types. Higher anemia prevalence was noted in gynecologic and colorectal carcinomas, 37.7% and 26.7%, respectively. The possible underlying justifications for this finding are because of the disorder of digestive function, unperceived and long term bleeding occurred in the colorectal tumor \[[@B19]\]. The other possible reason for gynecologic patients is all of them are females in gender and several of them also complained of vaginal bleeding history. This is in agreement with the reports made in China, colorectal (23.13%) scoring the 2nd rank followed by gastric (38.02%) and in Australia, where gynecologic (65%) was followed by urogenital (50%) \[[@B19], [@B23]\].

Our data also showed that bleeding history was found to be a risk factor for severity of anemia with *p*-value \< 0.05. This finding is similar to a study done in China showing that patients with bleeding were more likely to have more severe anemia as compared to patients without bleeding \[[@B19]\]. Gender and age category did not show any evidence of association with severity of anemia.

The majority of the anemia in our study was hypochromic (59%), which was different from the study done in China \[[@B19]\], in which 68.6% were normocytic. The underlying possible justification for this variation may be due to the difference in the study population and study period whereas the proportion of macrocytic anemia (1.9%) was similar to our result (2.1%).

Our study demonstrated that ECOG performance status and bleeding history showed a statistically significant association with the prevalence of anemia. This finding is similar to the result reported in China \[[@B19]\] (OR = 1.78, 95% CI; 1.29--2.45) and India \[[@B17]\], in which bleeding from tumor showed statistically significant association with the occurrence of anemia.

5. Conclusion {#sec5}
=============

In our study, the overall prevalence of anemia across different tumors is 23%. From the tumor types, gynecologic and colorectal scored higher anemia prevalence compared to others, which are 37.7% and 26.7%, respectively. Female and ≥ 65 aged patients showed a higher frequency of anemia when compared with male and \< 65 aged patients. Our study also revealed that ECOG PS and bleeding history indicated statistically significant association (*p* \< 0.05) with the occurrence and severity of anemia. The mean hemoglobin for initiating transfusion was 7.7 g/dl.

All authors would like extend their appreciation to nursing and laboratory staffs of Tikur Anbessa Specialized Hospital for their contribution in data collection and analysis. They also acknowledged study participants for their patience and cooperation in our study. The authors again appreciated Addis Ababa University for financially supporting this research during data collection. The authors also thank Addis Ababa University library for disclosing online this unpublished paper from which this manuscript was prepared and underway for publication \[[@B27]\].
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=================

*Limitations*. We have considered lack of conducting iron studies, blood cell morphology evaluation and using cross sectional study design due to budget constraints as our limitations and therefore we have recommended further investigations into the impact of anemia on disease status and treatment outcome using cohort study, iron studies and blood cell morphology evaluation to differentiate microcytic anemia.
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The supplementary material is a questionnaire by which we collected data.

###### 

Click here for additional data file.

![Distribution of severity of anemia among anemic respondents at TASH, Radiotherapy center, Addis Ababa from April to May 2014 (*n* = 97) \[Anemia grading: grade 1 or mild = 10−lower limit of normal g/dl; grade 2 or moderate = 8−10 g/dl; grade 3 or severe = 6.5−8 g/dl; grade 4 or life-threatening = \< 6.5 g/dl\].](AH2019-8279789.001){#fig1}

![Morphological classification of anemia among anemic patients with solid tumor attending TASH, Radiotherapy center, Addis Ababa from April to May 2014 (*n* = 97).](AH2019-8279789.002){#fig2}

###### 

Distribution of socio-demographic factors of the respondents at Radiotherapy center, TASH, Addis Ababa, 2014 (*n* = 422).

  Variables              Frequency   Percentage
  ---------------------- ----------- ------------
  *Age, in years*                    
  18--34                 78          18.5
  35--49                 153         36.3
  50--64                 135         32.0
  \>65                   56          13.3
  *Sex*                              
  Male                   144         34.1
  Female                 278         65.9
  *Residence*                        
  Rural                  195         46.2
  Urban                  227         53.8
  *Marital status*                   
  Single                 51          12.1
  Married                321         76.1
  Divorced               15          3.6
  Widowed                35          8.3
  *Level of education*               
  Literate               186         44.1
  Illiterate             236         55.9
  *Occupation status*                
  Employed               85          20.1
  Merchant               48          11.4
  Farmer                 94          22.3
  Student                17          4.0
  Day laborer            22          5.2
  House wife             156         37.0

###### 

Prevalence of anemia among associated factors in newly diagnosed solid cancers at TASH, Addis Ababa, Ethiopia, from April to May 2014 (*n* = 422).

  Factors            No (%)       HGB range, in g/dl   Mean HGB ± SD, in g/dl   Percentage with HGB ≤ 11 g/dl
  ------------------ ------------ -------------------- ------------------------ -------------------------------
  *Sex*                                                                         
  Male               144 (34.1)   4.8--18.9            13.28 ± 2.47             25 (17.4)
  Female             278 (65.9)   4.6--18.7            12.18 ± 2.1              72 (25.9)
  *Age categories*                                                              
  18--34             78 (18.5)    7.8--18.4            13.43 ± 2.15             10 (12.8)
  35--49             153 (36.3)   4.6--18.7            12.45 ± 2.4              40 (26.1)
  50--64             135 (32.0)   5.1--18.9            12.45 ± 2.2              30 (22.2)
  \>65               56 (13.3)    6.2--14.8            11.89 ± 2.11             17 (30.4)
  *Tumor types*                                                                 
  Gynecology         122 (28.9)   4.6--16.2            11.45 ± 2.32             46 (37.7)
  Breast             96 (22.7)    8.2--16.4            12.95 ± 1.52             14 (14.6)
  Colorectal         30 (7.1)     4.8--18.3            12.34 ± 2.83             8 (26.7)
  NPC                32 (7.6)     8.6--16.4            12.49 ± 1.95             8 (25.0)
  Sarcoma            29 (6.9)     7.2--18.4            13.09 ± 2.46             5 (17.2)
  Head and neck      19 (4.5)     7.8--15.9            13.29 ± 2.29             3 (15.8)
  Thyroid            14 (3.3)     10.9--15.7           13.19 ± 1.70             2 (14.3)
  Hepatoma           8 (1.9)      10.5--14.7           13.16 ± 1.19             1 (12.5)
  Others             72 (17.1)    4.8--18.9            13.43 ± 2.46             10 (13.9)
  *Tumor stages*                                                                
  Stage I            54 (12.8)    4.8--18.7            13.35 ± 2.35             7(13.0)
  Stage II           129 (30.6)   4.8--18.3            12.53 ± 2.30             32 (24.8)
  Stage III          174 (41.2)   4.6--18.9            12.15 ± 2.39             51 (29.3)
  Stage IV           65 (15.4)    8.3--17.7            13.02 ± 1.66             7 (10.8)
  *ECOG PS*                                                                     
  Grade 0            78 (18.5)    7.9--18.7            13.04 ± 2.09             12 (15.4)
  Grade 1            154 (36.5)   6.9--18.9            12.77 ± 2.19             33 (21.4)
  Grade 2            87 (20.6)    4.6--17.7            11.95 ± 2.56             26 (29.9)
  Grade 3            79 (18.7)    6.2--18.4            12.17 ± 2.19             24 (30.4)
  Grade 4            24 (5.7)     5.1--15.9            13.07 ± 2.32             2 (8.3)

ECOG performance score: 0 = fully active; 1 = restricted in physically strenuous activity but able to carry out light work or activities; 2 = ambulatory and capable of self-care but unable to work; 3 = capable of only limited self-care, confined to bed or chair \> 50% of time; 4 = completely disabled, totally confined to bed or chair.

  --------- ------------ -------- --------------
  \<80      Microcytic   \<32     Hypochromic
  80--100   normocytic   32--36   Normochromic
  \>100     Macrocytic   \>36     Polychromic
  --------- ------------ -------- --------------

*Source:* Taken from Wintrobe\'s Clinical hematology, 12th edition and McGraw-Hill\'s Manual of laboratory and diagnostic tests, 2008).

###### 

Relationships between severity of anemia and factors among newly diagnosed solid cancer patients at TASH, Addis Ababa, Ethiopia from April to May 2014 (*n* = 97).

  Factors              Severity of anemia   *X* ^2^      *p*-value                       
  -------------------- -------------------- ------------ ------------ ---------- ------- -------
  *Sex*                                                                                  
  Male                 14 (56.0%)           7 (8.0%)     2 (8.0%)     2 (8.0%)           
  Female               30 (41.7%)           30 (41.7%)   9 (12.5%)    3 (4.2%)   2.609   0.498
                                                                                         
  *Age (years)*                                                                          
  18--64               37 (46.2%)           29 (36.2%)   10 (12.5%)   4 (5.0%)           
  ≥65                  7 (41.2%)            8 (47.1%)    1 (5.9%)     1 (5.9%)   1.072   0.829
                                                                                         
  *Bleeding history*                                                                     
  NO                   31 (59.6%)           14 (26.9%)   5 (9.6%)     2 (3.8%)           
  YES                  13 (28.9%)           23 (51.1%)   6 (13.3%)    3 (6.7%)   9.387   0.024

###### 

Relationships between prevalence of anemia and factors among newly diagnosed solid cancer patients at TASH, Addis Ababa, Ethiopia from April to May 2014 (*n* = 422).

  Variables       Anemia        COR (95% C.I)   *p*-value                 AOR (95% C.I)   *p*-value                 
  --------------- ------------- --------------- ------------------------- --------------- ------------------------- -------
  *Gender*                                                                                                          
  Male            119 (82.6%)   25 (17.4%)      1                                         1                         
  Female          206 (74.1%)   72 (25.9%)      1.664 (1.001--2.765)^∗^   0.049           1.094 (0.504--2.374)      0.819
                                                                                                                    
  *Age (years)*                                                                                                     
  18--34          68 (87.2%)    10 (12.8%)      1                                         1                         
  35--49          113 (73.9%)   40 (26.1%)      2.407 (1.131--5.124)^∗^   0.023           1.956 (0.845--4.526)      0.117
  50--64          105 (77.8%)   30 (22.2%)      1.943 (0.892--4.230)      0.094           1.237 (0.516--2.961)      0.634
  ≥65             39 (69.6%)    17 (30.4%)      2.964 (1.236--7.108)^∗^   0.015           2.422 (0.925--6.342)      0.072
                                                                                                                    
  *Bleeding*                                                                                                        
  No              278 (86.1%)   45 (13.9%)      1                                         1                         
  Yes             58 (58.6%)    41 (41.4%)      4.343 (2.649--7.121)^∗^   0.001           3.628 (1.800--7.314)^∗^   0.001
                                                                                                                    
  *Tumor type*                                                                                                      
  Gynecology      76 (62.3%)    46 (37.7%)      3.753 (1.752--8.038)^∗^   0.001           1.444 (0.480--4.346)      0.514
  Breast          82 (85.4%)    14 (14.6%)      1.059 (0.441--2.542)      0.899           1.005 (0.355--2.850)      0.992
  Colorectal      22 (73.3%)    8 (26.7%)       2.255 (0.790--6.438)      0.129           1.688 (0.544--5.231)      0.365
  NPC             24 (74.9%)    8 (25.0%)       2.067 (0.729--5.860)      0.172           2.027 (0.661--6.218)      0.217
  Sarcoma         24 (82.8%)    5 (17.2%)       1.292 (0.400--4.172)      0.669           1.470 (0.422--5.124)      0.545
  Head and neck   16 (84.1%)    3 (15.9%)       1.162 (0.286--4.725)      0.833           0.849 (0.183--3.936)      0.835
  Thyroid         12 (85.7%)    2 (14.3%)       1.033 (0.201--5.323)      0.969           1.234 (0.206--7.408)      0.818
  Hepatoma        7 (87.5%)     1 (12.5%)       0.886 (0.098--7.987)      0.914           0.874 (0.086--8.842)      0.909
  Others          62 (86.1%)    10 (13.9%)      1                                         1                         
                                                                                                                    
  *Tumor stage*                                                                                                     
  Stage I         47 (87.0%)    7 (13.0%)       1                                         1                         
  Stage II        97 (75.2%)    32 (24.8%)      2.215 (0.911--5.388)      0.08            1.487 (0.564--3.920)      0.423
  Stage III       123 (70.7%)   51 (29.3%)      2.784 (1.180--6.569)^∗^   0.019           1.503 (0.565--3.994)      0.414
  Stage IV        58 (89.2%)    7 (10.8%)       0.810 (0.265--2.474)      0.712           0.827 (0.240--2.858)      0.764
                                                                                                                    
  *ECOG PS*                                                                                                         
  Grade 0         67 (19.9%)    11 (12.8%)      1                                         1                         
  Grade 1         127 (37.8%)   27 (31.4%)      1.500 (0.726--3.099)      0.273           2.013 (0.918--4.415)      0.081
  Grade 2         61 (18.2%)    26 (30.2%)      2.344 (1.088--5.050)^∗^   0.030           3.102 (1.345--7.152)^∗^   0.008
  Grade 3         59 (17.6%)    20 (23.3%)      2.400 (1.100--5.235)^∗^   0.028           3.344 (1.410--7.927)^∗^   0.006
  Grade 4         22 (6.5%)     2 (2.3%)        0.500 (0.104--2.410)      0.388           0.952 (0.168--5.384)      0.955

Constants are indicated by 1; whereas ^∗^ indicates statistical significant association.
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